Breast cancer drug approvals: the latest news

Written by Jade Parker (Senior Editor) & Lucy Welsh (Digital Editor)
Breast Drug approvals News
breast cancer drug approvals

This ongoing roundup article highlights the latest drug approvals for breast cancer from major regulatory bodies. Stay tuned to discover the latest therapeutic advancements for breast cancer patients. Kisqali® (ribociclib) with an aromatase inhibitor Indication: HER2-negative lymph node-negative early breast cancer at high risk of recurrence Approving body: NICE Approved: 17 July 2025 In April 2025, NICE approved this treatment combination for early breast cancer patients whose cancer has spread to nearby lymph nodes (lymph node-positive) through interim funding from the Cancer Drugs Fund. In February 2025, the MHRA approved the same combination based on results from the NATALEE Phase...

To view this content, please register now for access

It's completely free